ADO and neoplasm: Additionally, the engineered biohybrid Bc@AZTF was designed to interference of ATP-ADO Axis, which can actively enrich in tumor sites and respond to the acidic TME, consuming intracellular ATP content while inhibiting the ATP-ADO axis to reduce ADO accumulation, thereby alleviating ADO-mediated immunosuppression (89).